Clover Health Investments, Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLOV research report →
Range $5 – $6
Price Chart
About the company
Clover Health Investments, Corp. is a U. S.
- CEO
- Andrew Toy
- IPO
- 2020
- Employees
- 724
- HQ
- Wilmington, DE, US
Get TickerSpark's AI analysis on CLOV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.98B
- P/E
- 221.76
- Fwd P/E
- 61.89
- PEG
- 1.05
- P/S
- 0.73
- P/B
- 5.13
- EV/EBITDA
- 119.13
- Div Yield
- 0.00%
- Gross Margin
- 18.86%
- Op Margin
- 0.45%
- Net Margin
- 0.45%
- ROE
- 3.52%
- ROIC
- 3.05%
Latest fiscal year · YoY change
- Revenue
- $1.92B+40.3%
- Gross Profit
- $355.88M-2.4%
- Op Income
- $-85,529,000
- Net Income
- $-85,549,000-98.9%
- EPS
- $-0.17-93.6%
- OCF Growth
- -292.1%
- FCF Growth
- -307.2%
- 52W High
- $5.59
- 52W Low
- $1.58
- 50D MA
- $4.61
- 200D MA
- $3.70
- Beta
- 2.48
- RSI (14)
- 31
- Avg Volume
- 4.42M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Clover said Q3 results strengthened its path to first full-year GAAP profitability in 2026, while early 2027 AEP trends and 2028 Stars create confidence in further growth and earnings expansion.· November 4, 2026
- Q3 revenue rose 53% year over year to $759 million, gross profit rose 77% to $130 million, adjusted EBITDA was $16 million, and GAAP net income was $6 million.
- Through the first 9 months, membership grew 49% to about 157,000, revenue rose 57% to about $2.3 billion, gross profit increased to $442 million, and GAAP net income improved to $62 million.
- Management raised the low end of full-year 2026 guidance across every metric and still expects first full-year GAAP net income profitability.
- The flagship PPO earned 5 Stars for payment year 2028, while the HMO earned 4.5 Stars, leaving 100% of members in plans rated at least 4.5 Stars.
- Management said early AEP results are strong and that 2027 should benefit from cohort maturation, higher Clover Assistant coverage, and operating leverage, but no formal 2027 guidance was given.
Q3 2026 total revenue was $759 million, up 53% year over year; consolidated gross profit was $130 million, up 77%; adjusted EBITDA was $16 million versus $2 million a year ago; and GAAP net income was $6 million versus a $24 million loss last year. For the first 9 months, average Medicare Advantage membership grew 49% year over year to approximately 157,000, revenue increased 57% to approximately $2.3 billion, gross profit rose by $161 million to $442 million, adjusted EBITDA more than doubled to $97 million, and GAAP net income improved by $98 million to $62 million. Full-year 2026 guidance was raised at the low end and now calls for average Medicare Advantage membership of 157,000 to 158,000, revenue of $2.97 billion to $3 billion, consolidated gross profit of $540 million to $555 million, adjusted EBITDA of $75 million to $85 million, and GAAP net income of $25 million to $35 million. Management said the fourth quarter should reflect lower gross profit from normal medical cost seasonality and higher SG&A from planned AEP investments, and reiterated that 2026 is expected to be the company’s first full year of GAAP net income profitability.
Andrew Toy framed the quarter as evidence that Clover’s model is working at scale, driven by its health plan, Clover Assistant, and a disciplined financial approach. He emphasized that the company is entering 2027 with strong 2028 Stars, industry-leading HEDIS performance, and early AEP traction, while saying Clover is built to manage true clinical quality and total cost of care rather than simply optimize for Stars. His tone was upbeat and confident, but he repeatedly noted that 2027 guidance is not being issued yet and that AEP is still underway.
Clay Thornton focused on the financial momentum and the mechanics behind future earnings expansion. He cited 9M results of about $2.3 billion in revenue, $442 million in gross profit, $97 million in adjusted EBITDA, and $62 million in GAAP net income, then highlighted Q3 adjusted SG&A of $114 million and year-to-date adjusted SG&A at about 15% of revenue, improved by 120 basis points year over year. He also pointed to a strong balance sheet with approximately $513 million of cash, cash equivalents and investments, no debt, and $203 million of cash flow from operations through September, saying liquidity should support growth, capital needs, and continued investment.
Analysts pressed on Clover Assistant coverage, cohort economics by geography, AEP switching opportunities in New Jersey, and whether 5 Stars might change marketing or growth strategy. Management said CA coverage is tracking ahead of last year and generally ahead across cohorts and geographies, with New Jersey strongest because the network is deepest there. They also said Braven’s planned exit in New Jersey and broader PPO retrenchment are already showing up in early AEP results, while any change to marketing or expansion plans beyond New Jersey and Georgia will wait until after AEP. On litigation and Stars policy, Andrew Toy said Clover believes the original court decision was well decided, is planning for scenarios but does not want to speculate before the appeal is resolved, and would prefer a more individualized, data-driven quality system.
The call suggested Clover is converting rapid membership growth into improving profitability, with gross profit, EBITDA, and GAAP earnings all moving sharply higher. Management sees further upside from maturing cohorts, accelerating Clover Assistant coverage, and operating leverage, and it has a strong starting point with 5 Stars for the PPO in 2028 and early AEP strength.
The company still faces meaningful execution and policy risk, including the unresolved government appeal and uncertainty around how much of 2027’s benefit will be reinvested versus kept as earnings. Management also acknowledged that a larger 2027 member influx could be a near-term drag on earnings, and that fourth-quarter seasonality will pressure gross profit while SG&A rises with AEP investments.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.3%
- Shares Outstanding
- 531.16M
- Float Shares
- 410.46M
of shares held by institutions
242 13F filers
Buy/sell ratio 0.18. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 36.51M | ▲ 1.40M |
| Vanguard Group Inc | 23.49M | ▲ 425.90K |
| Vanguard Capital Management LLC | 18.38M | ▲ 344.11K |
| Geode Capital Management, LLC | 11.12M | ▲ 269.92K |
| State Street Corp | 10.69M | ▲ 513.37K |
| Nuveen, LLC | 7.82M | ▲ 1.53M |
| Vanguard Portfolio Management LLC | 7.59M | ▲ 3.12M |
| Charles Schwab Investment Management Inc | 5.52M | ▲ 220.71K |
| Renaissance Technologies LLC | 4.55M | ▲ 1.75M |
| Northern Trust Corp | 3.77M | ▲ 466.02K |
| Dimensional Fund Advisors LP | 3.37M | ▲ 222.74K |
| Vanguard Fiduciary Trust Co | 3.08M | ▲ 159.64K |
Held by 243 ETFs
Biggest fund positions in CLOV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | THORNTON JOSEPH CLAY | sell | 22,099 |
| Nov 4, 26 | OLDAKOWSKI JOSEPH FRANK | other | 186,403 |
| Nov 4, 26 | THORNTON JOSEPH CLAY | other | 328,947 |
| Oct 20, 26 | Soares Karen | sell | 19,275 |
| Oct 19, 26 | Reynoso Jamie L. | sell | 4,066 |
| Oct 15, 26 | Toy Andrew | sell | 62,176 |
| Oct 15, 26 | Soares Karen | sell | 14,673 |
| Oct 15, 26 | THORNTON JOSEPH CLAY | sell | 4,591 |
| Oct 15, 26 | Wai Conrad | sell | 23,627 |
| Oct 15, 26 | Reynoso Jamie L. | sell | 18,273 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLOV coverage
Recent articles, reports, and earnings notes.
No research on CLOV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLOV report →Clover Health Investments Sees 2027 Growth as Rival Exits New Jersey
marketbeat.com · Nov 9
Clover Health Investments, Corp. (CLOV) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
Clover Health's Best Earnings Years May Still Be Ahead
seekingalpha.com · Nov 6
Clover Health Investments, Corp. (CLOV) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
What Clover Health Investments (CLOV) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
Clover Health Reports Third Quarter 2026 Results
globenewswire.com · Nov 4
Clover Health to Participate in Upcoming UBS Global Healthcare Conference
globenewswire.com · Oct 26
Clover Health Investments (NASDAQ:CLOV) Insider Karen Soares Sells 14,673 Shares of Company Stock
defenseworld.net · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.